Results 91 to 100 of about 1,744 (184)

The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI

Global and Regional Health Technology Assessment
Acute bacterial skin and skin structure infections (ABSSSIs) represent a common and costly healthcare burden, accounting for millions of annual infections and billions of dollars in healthcare expenditures. Dalbavancin is a long-acting glycopeptide antibiotic that has demonstrated efficacy and safety in the treatment of ABSSSIs.
openaire   +3 more sources

A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study [PDF]

, 2018
Delafloxacin es una fluoroquinolona intravenosa (IV)/oral con actividad sobre los organismos anaeróbicos gram-positivos, gram-negativos, atípicos, incluyendo el Staphylococcus aureus resistente a methicillin.
Cammarata, Sue, Cruz-Saldariaga, María, Lawrence, Laura, McManus, Alison, O’Riordan, William, Quintas, Megan, ShuJui Liang, Teras, Juri   +7 more
core  

Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

Infection and Drug Resistance, 2016
Travis M Jones,1,2 Steven W Johnson,1,3 V Paul DiMondi,1,4 Dustin T Wilson,1,2 1Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, 2Department of Pharmacy, Duke University Hospital, Durham ...
Jones TM, Johnson SW, DiMondi VP, Wilson DT   +3 more
doaj  

Dalbavancin in the Community Emergency Department [PDF]

, 2020
Introduction Dalbavancin is an antibiotic within the class of medications known as lipoglycopeptides. This medication is given to patients presenting to the hospital with acute skin and skin-structure infections (ABSSSI).
Johnson, Wesley
core   +1 more source

Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study [PDF]

, 2015
Background: The treatment of complicated skin and soft tissue infections (cSSTI) is challenging and many patients do not receive adequate first-line therapy. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe
A Berger, D Nathwani, Francesco Blasi, GH Talbot, GR Corey, HD Friedland, Helmut Ostermann, J Edelsberg, J Edelsberg, J Garau, J Joo, Javier Garau, Jesús Medina, Kyle McBride, MD Zilberberg, MH Wilcox, MJ Zervos, MS Dryden, P Prokocimer, S Amara, SY Lee, US Food and Drug Administration   +21 more
core   +3 more sources

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs

Drugs in Context, 2018
Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern.
Pedro Luis Gonzalez, Urania Rappo , Karthik Akinapelli, Jennifer S McGregor , Sailaja Puttagunta, Michael W Dunne   +5 more
doaj   +1 more source

Development of a Patient-Reported outcome Instrument (Skinfect-Pro) To Standardize And Qualify Symptoms of Acute Bacterial Skin And Skin Structure Infection (Absssi) FNIH Biomarkers Consortium CABP ABSSSI Project Team ‘3 [PDF]

Value in Health, 2015
Powers, J.H., Howard, K., Saretsky, T., Clifford, S., Hoffmann, S.C., Talbot, G.H., Cimms, T.A., Llorens, L.   +7 more
openaire   +2 more sources

Dalbavancin utilization registry investigating value and effectiveness (DRIVE): Outcomes report on real-world use

Clinical Infection in Practice
Objectives: Dalbavancin has potent activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, and is approved for treatment of acute bacterial skin and skin structure infections (ABSSSI).
Bruce M. Jones, Kerry O. Cleveland, Pedro L. Gonzalez, Urania Rappo, Todd Riccobene, Rosie D. Lyles   +5 more
doaj   +1 more source

Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience [PDF]

, 2019
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 hospitals in Italy (June 2016\u2013March 2018).
Artioli, S., Bassetti, M., Capone, A., Carannante, N., Castaldo, N., Cattelan, A., Cipriani, L., Coletto, D., Digaetano, M., Grossi, P., Losito, A. R., Luzzati, R, Mastroianni, C. M., Mussini, C., Nicole, S., Peghin, M., Righi, E., Russo, A., Tascini, C., Tumbarello, M., Vena, A &   +20 more
core   +1 more source

A Us Hospital Economic Impact Model for Oritavancin In Absssi Patients With Risk of Mrsa Infections [PDF]

Value in Health, 2014
Wu, C., Fortier, K.J., LaPensee, K., Fan, W., Mitchell, M., Cyr, P.L., Jensen, I.S.   +6 more
openaire   +3 more sources